XSHG
688670
, Last price
Name
Jiangsu GDK Biotechnology Co Ltd
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
5.91%
Rev. 5Y
-28.10%
Div Yld LY
—
Div Yld TTM
—
Revenues
113m
+40.13%
Net income
-173m
L+85.53%
CFO
0
P
Dividend
May 26, 20230.28 /sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Jiangsu gdk Biotechnology Co., Ltd. operates as a biotechnology firm specializing in the comprehensive research, development, manufacturing, and commercialization of human vaccines, alongside providing related services. Its current portfolio includes a quadrivalent split-virus influenza vaccine and a lyophilized human rabies vaccine. The company's pipeline is strategically focused on preventing major infectious diseases such as influenza, rabies, chickenpox, shingles, and pneumonia. This enterprise was established in 2008 and is headquartered in Taizhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||